(Q36131766)

12 August 2017

1 reference

title

Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus (English)

1 reference

12 August 2017

1 reference

1 reference

2

John E Gerich

1 reference

12 August 2017

Ervin Szoke

1

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

Comprehensive Therapy

1 reference

12 August 2017

31

1 reference

12 August 2017

2

1 reference

12 August 2017

106-112

1 reference

https://scigraph.springernature.com/pub.10.1007/s12019-005-0005-y

12 August 2017

0 references

cites work

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Is insulin resistance the principal cause of type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Relative conributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Insulin resistance: the fundamental trigger of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Insulin resistance: a chicken that has come to roost

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Free fatty acids and pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Free fatty acids, insulin resistance, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

5' flanking variants of resistin are associated with obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Adiponectin and Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The role of the novel adipocyte-derived hormone adiponectin in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

ACRP30, a new hormone controlling fat and glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Obesity, metabolic syndrome, and coronary atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Effect of dietary lipid on insulin action. Clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Drug-induced disorders of glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Strategies and prospects for finding insulin resistance genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Genetics of type 2 diabetes and insulin resistance: knowledge from human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Role of insulin resistance in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

IRS proteins and beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Banting lecture 1990. Beta-cells in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Evolution of beta-cell dysfunction in impaired glucose tolerance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

The burden of treatment failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12019-005-0005-Y

10.1007/S12019-005-0005-Y

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15901939